Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
1. An immunogenic composition comprising a pharmaceutically-acceptable carrier, an immunostimulatory amount of an adjuvant and a particulate composition comprising a polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2, wherein the polypeptide does not comprise a full length ICP4 polypeptide.
2. A method of treating a subject suffering from HSV-2 infection, comprising administering to the subject an effective amount of the immunogenic composition according to claim 1 .
3. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the immunogenic composition inhibits HSV-2 symptoms.
4. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the immunogenic composition reduces the number of herpetic lesions.
5. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the immunogenic composition reduces the number of days a subject experiences herpetic lesions.
6. A method of treating a subject suffering from HSV-2 infection, comprising:
administering to the subject an initial dose of an effective amount of an immunogenic composition; and
administering to the subject one or more additional doses of the immunogenic composition at a specified time interval after receiving the initial dose;
wherein the immunogenic composition comprises a formulation comprising a pharmaceutically-acceptable carrier, an immunostimulatory amount of an adjuvant and a particulate composition comprising a polypeptide comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 2.
7. The method of claim 6 , comprising administering one or more additional doses of the immunogenic composition 1 month, 2 months, 4 months, 6 months or 12 months after receiving the initial dose.
8. The method of claim 6 , wherein the one or more additional doses comprises a first and a second additional dose.
9. The method of claim 6 , wherein the method reduces the number of herpetic lesions at the onset of HSV-2 infection.
10. The method of claim 6 , wherein the one or more additional doses are administered in a dose escalation manner, such that at least one successive administration of the immunogenic composition contains a higher concentration of the immunogenic composition than at least one previous dose.
11. The method of claim 6 , wherein the one or more additional doses are administered in a manner such that at least one successive administration of the immunogenic composition contains a lower concentration of the immunogenic composition than at least one previous dose.
12. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the immunogenic composition activates a T cell response to one or more HSV-2 antigens in the subject.
13. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the immunogenic composition increases a T cell response to one or more HSV-2 antigens in a subject.
14. The immunogenic composition of claim 1 , wherein upon administration to a subject infected with HSV-2, the subject exhibits a delayed onset of symptoms or reduced severity of HSV-2 symptoms.
15. The method of claim 2 , wherein administering the immunogenic composition comprises intravenous, intraperitoneal, intramuscular, intradermal, subcutaneous, transdermal, subdermal, intracranial, intranasal, mucosal, anal, vaginal, oral, sublingual, buccal, inhaled, or topical administration.
16. The method of claim 15 , wherein administering the immunogenic composition comprises subcutaneous, intranasal, or mucosal administration.
17. The immunogenic composition of claim 1 , wherein the particulate composition further comprises an HSV gD2 polypeptide.
18. The immunogenic composition of claim 1 , wherein the particulate composition further comprises an HSV gD2 polypeptide lacking a transmembrane and/or lacking a cytoplasmic domain.
19. The immunogenic composition of claim 1 , wherein the particulate composition further comprises a second polypeptide consisting of the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 4 or SEQ ID NO: 5.
20. The immunogenic composition of claim 1 , wherein the polypeptide is lacking 1-20 amino acids from the N-terminus, C-terminus, or both.
21. The immunogenic composition of claim 1 , wherein the polypeptide consists of an amino acid sequence having at least 90% identity to SEQ ID NO:2.